Metastatic Pancreatic Ductal Adenocarcinoma Clinical Trials

15 recruiting

Metastatic Pancreatic Ductal Adenocarcinoma Trials at a Glance

17 actively recruiting trials for metastatic pancreatic ductal adenocarcinoma are listed on ClinicalTrialsFinder across 6 cities in 13 countries. The largest study group is Phase 2 with 8 trials, with the heaviest enrollment activity in St Louis, Portland, and Guangzhou. Lead sponsors running metastatic pancreatic ductal adenocarcinoma studies include OHSU Knight Cancer Institute, Washington University School of Medicine, and Dr Daniel Croagh.

Browse metastatic pancreatic ductal adenocarcinoma trials by phase

Treatments under study

About Metastatic Pancreatic Ductal Adenocarcinoma Clinical Trials

Looking for clinical trials for Metastatic Pancreatic Ductal Adenocarcinoma? There are currently 15 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Metastatic Pancreatic Ductal Adenocarcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Metastatic Pancreatic Ductal Adenocarcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 117 of 17 trials

Recruiting
Phase 1Phase 2

Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma

Stage IV Pancreatic Cancer AJCC v8Metastatic Pancreatic Ductal Adenocarcinoma
Roswell Park Cancer Institute35 enrolled1 locationNCT07214298
Recruiting
Phase 1

CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer

Stage III Pancreatic Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8Metastatic Pancreatic Ductal Adenocarcinoma+1 more
National Cancer Institute (NCI)43 enrolled26 locationsNCT05685602
Recruiting
Phase 1

MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Pancreatic CancerMetastatic Pancreatic Ductal AdenocarcinomaCancer of the Pancreas
Washington University School of Medicine51 enrolled1 locationNCT06648434
Recruiting
Phase 2Phase 3

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

Metastatic Pancreatic Ductal AdenocarcinomaCachexia
Pfizer982 enrolled114 locationsNCT06989437
Recruiting
Phase 1

Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer

Metastatic Pancreatic Ductal AdenocarcinomaStage IV Colorectal Cancer AJCC v7Stage IV Pancreatic Cancer AJCC v6 and v7+3 more
M.D. Anderson Cancer Center300 enrolled1 locationNCT02600949
Recruiting
Phase 1Phase 2

The KN510713 Study in Combination With mFOLFIRINOX

Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
New Cancer Cure-Bio Co.,Ltd.30 enrolled1 locationNCT07114861
Recruiting
Phase 1Phase 2

ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma

Metastatic Pancreatic Ductal Adenocarcinoma
Washington University School of Medicine61 enrolled1 locationNCT06904378
Recruiting
Early Phase 1

OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma

Stage II Pancreatic Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8+2 more
OHSU Knight Cancer Institute12 enrolled1 locationNCT07089940
Recruiting
Early Phase 1

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

Stage II Pancreatic Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8+5 more
OHSU Knight Cancer Institute90 enrolled1 locationNCT04005690
Recruiting
Phase 1

SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells

Breast Cancer MetastaticPancreatic CancerHER2-negative Breast Cancer+9 more
General Oncology, Inc.24 enrolled2 locationsNCT04150042
Recruiting
Phase 3

Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

Metastatic Pancreatic Ductal Adenocarcinoma
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.566 enrolled70 locationsNCT07165951
Recruiting
Phase 2

PULSAR in Systemic Therapy for Pancreatic Cancer

Borderline Resectable Pancreatic Ductal AdenocarcinomaLocally Advanced Pancreatic Ductal AdenocarcinomaOligometastatic Pancreatic Ductal Adenocarcinoma
Samsung Medical Center47 enrolled1 locationNCT07269626
Recruiting

Hyperpolarized 13C MRI to Predict Response in Pancreatic Cancer

Pancreatic Ductal AdenocarcinomaMetastatic Pancreatic Ductal AdenocarcinomaLocally Advanced Pancreatic Ductal Adenocarcinoma
University of California, San Francisco70 enrolled1 locationNCT06600906
Recruiting
Phase 2

Utility of ctDNA in Early Switch of First-line mFOLFIRINOX in Metastatic Pancreatic Ductal Adenocarcinoma

Pancreatic Ductal AdenocarcinomaMetastatic Pancreatic Ductal Adenocarcinoma
University of Miami50 enrolled1 locationNCT07096362
Recruiting
Phase 2

The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation

Metastatic Pancreatic CancerMetastatic Pancreatic Ductal Adenocarcinoma
Benjamin Spieler20 enrolled1 locationNCT06843551
Recruiting
Phase 2

A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC)

Metastatic Pancreatic Ductal Adenocarcinoma
Belgian Group of Digestive Oncology134 enrolled13 locationsNCT05472259
Recruiting

Molecular Evaluation of Pancreatic Cancer

Unresectable or metastatic pancreatic ductal adenocarcinoma or recurrent disease
Dr Daniel Croagh150 enrolled10 locationsACTRN12620000762954